Compare Build A Bear Workshop Inc (BBW) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Build A Bear Workshop Inc vs Neurocrine Biosciences Inc — how do they compare? Build A Bear Workshop Inc trades at $34.39 (market cap $412.61M), while Neurocrine Biosciences Inc trades at $171.65 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is far larger — about 41.9× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.8% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| BBW | NBIX | |
|---|---|---|
Market Cap | $412.61M | $17.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $75.85 | $180.55 |
52-Week Low | $29.84 | $123.10 |
Enterprise Value | $512.05M | $16.39B |
Dividend Yield | 2.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Build-A-Bear Workshop (BBW) trades at $33.62, down 2.32% with a bullish technical signal and strong valuation metrics including a P/E of 7.71 and P/S of 0.81. The company maintains solid profitability with 10.48% net margins and 35.87% ROE, while recent earnings have consistently beaten expectations. CEO transition to Chris Hurt in June 2026 and new product launches support growth initiatives.
BBW presents compelling value with analyst consensus target of $62.50 (86% upside) and 73% buy ratings. Strong fundamentals and debt-free balance sheet support long-term growth, though near-term headwinds include consumer spending pressure and international expansion execution risks.
Neurocrine Biosciences (NBIX) trades at $174.10, down 1.7% on the day but maintains strong technical momentum with bullish moving averages and support at $173. The company demonstrates robust fundamentals with Q1 2026 revenue growth of 44% year-over-year to $811 million and consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected. Recent pipeline advancements include Phase 2 studies for crinecerfont and positive VYKAT XR data presented at ENDO 2026.
NBIX presents compelling growth prospects with analyst consensus price target of $195.75 (12% upside) and 86% buy ratings. Key opportunities include blockbuster drug performance and strategic acquisitions, while risks involve clinical trial outcomes and competitive pressures in neuroscience therapeutics. The stock's current valuation at 26.5x P/E reflects growth expectations but requires continued execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Build A Bear Workshop Inc
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
